Candel Therapeutics

Candel Therapeutics is a clinical-stage biotechnology company focused on developing viral immunotherapies to fight cancer. They leverage the power of genetically engineered viruses to selectively induce tumor cell death and stimulate a targeted immune response against cancer. Their off-the-shelf therapies, designed for individualized cancer responses, are based on two platforms: an adenovirus platform, which includes their lead product candidate CAN-2409, and a herpes simplex virus (HSV) platform, with CAN-3110 as its lead candidate. Their goal is to improve survival and maintain quality of life for patients with early- to late-stage cancer across various indications.

Candel Therapeutics is committed to developing innovative cancer treatments. They are actively engaged in clinical trials, particularly in prostate cancer, lung cancer, brain cancer, and pancreatic cancer. Their research suggests that their viral immunotherapies may revolutionize cancer treatment by utilizing a unique mechanism of action that combines an anti-tumor component with an immune-stimulatory component. This approach has the potential to create a long-lasting, individualized response, tailored to each patient's unique cancer. Candel Therapeutics is a promising player in the field of cancer immunotherapy, aiming to bring new and effective therapies to patients in need.

Candel Therapeutics provides information about job flexibility in their general "Careers" page. They describe the company's culture as fostering cognitive diversity with freedom and accountability, encouraging their teams to be inspired, creative, and collaborative. While they don't explicitly mention remote work or flexible schedules, their focus on a collaborative environment and employee empowerment suggests a willingness to explore flexible work arrangements.

Candel Therapeutics is a biotechnology company focused on developing innovative viral immunotherapies to improve the lives of cancer patients. Their mission is to save, extend, and improve the lives of patients through the use of their proprietary virus-based approaches, eliciting a broad and potent immune response against solid tumors and their metastases. Their commitment to patient-centric research and development is evident in their focus on creating personalized cancer treatments with favorable benefit-to-risk profiles, striving for both efficacy and tolerability across disease stages.

Candel Therapeutics fosters a culture that prioritizes innovation, collaboration, and a shared passion for improving patient lives. The company encourages cognitive diversity, valuing freedom, accountability, and efficiency. This translates to an environment where employees are inspired to challenge each other, think creatively, and work together in a trusting and supportive atmosphere.

Candel Therapeutics fosters a culture of cognitive diversity, emphasizing freedom and accountability within a multidisciplinary team. They value inspiration, creativity, challenge, efficiency, collaboration, and trust, actively seeking new team members who share their passion and commitment to making a difference.